To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).

Start Date01 Aug 2021

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

[+3]

NCT03015519 / WithdrawnPhase 3

A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients

The incidence of Type 2 Diabetes Mellitus (T2DM) is increasing day by day but the treatment options are limited in children and adolescents. Albiglutide, approved for the treatment of T2DM in adult population, is a novel analogue of glucagon-like peptide-1 (GLP-1) with a sufficiently long half-life to permit once a week injection. The study will be conducted in 2 parts: Part A is a single dose pharmacokinetic (PK) study to confirm the dose and safety of albiglutide in pediatric subjects aged 10 to less than 18 years and Part B is a randomized double-blind placebo controlled study to evaluate the safety and efficacy (glycemic control) of albiglutide in the pediatric population. Treatment duration in Part B is 52 weeks (24 weeks double-blind placebo-controlled and 28 weeks open-label during which all subjects will receive albiglutide). Approximately 210 eligible male and female subjects will be included in the study.

Start Date14 Aug 2017

Sponsor / Collaborator

GSK Plc

NCT02750930 / TerminatedPhase 4

An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus

Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US) Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory agencies. This is a 26 week, open-label, single group, multicenter, extension study to Study 200952. This extension study will provide extended safety, tolerability and immunogenicity data for the albiglutide liquid drug product. This extension study will comprise 2 study periods: treatment (26 weeks) and post-treatment follow-up (8 weeks). A maximum of 300 subjects will be eligible to take part in this extension study.

Start Date07 Oct 2016

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Albiglutide

100 Translational Medicine associated with Albiglutide

100 Patents (Medical) associated with Albiglutide

216

Literatures (Medical) associated with Albiglutide

29 Nov 2023·Journal of agricultural and food chemistry

Optimization of Protein Folding for Improved Secretion of Human Serum Albumin Fusion Proteins in Saccharomyces cerevisiae

Article

Author: Li, Yanling ; Zheng, Lin ; Xiao, Chufan ; Huang, Mingtao ; Qin, Ling ; Pan, Yuyang ; Zhao, Mouming

The successful expression and secretion of recombinant proteins in cell factories significantly depend on the correct folding of nascent peptides, primarily achieved through disulfide bond formation. Thus, optimizing cellular protein folding is crucial, especially for proteins with complex spatial structures. In this study, protein disulfide isomerases (PDIs) from various species were introduced into Saccharomyces cerevisiae to facilitate proper disulfide bond formation and enhance recombinant protein secretion. The impacts of these PDIs on recombinant protein production and yeast growth metabolism were evaluated by substituting the endogenous PDI1. Heterologous PDIs cannot fully compensate the endogenous PDI. Furthermore, protein folding mediators, PDI and ER oxidoreductase 1 (Ero1), from different species were used to increase the production of complex human serum albumin (HSA) fusion proteins. The validated folding mediators were then introduced into unfolded protein response (UPR)-optimized strains, resulting in a 7.8-fold increase in amylase-HSA and an 18.2-fold increase in albiglutide compared with the control strain. These findings provide valuable insights for optimizing protein folding and expressing HSA-based drugs.

08 Aug 2023·Journal of the American College of Cardiology

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.

Article

Author: Vasques-Nóvoa, Francisco ; Leiter, Lawrence A ; McMurray, John J V ; Borges-Canha, Marta ; Carvalho, Davide ; Ferreira, João Pedro ; Granger, Christopher B ; Neves, João Sérgio ; Green, Jennifer B ; Leite-Moreira, Adelino ; Del Prato, Stefano ; Hernandez, Adrian F

BACKGROUND:

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear.

OBJECTIVES:

The aim of this study was to evaluate the effects of GLP-1 RAs on cardiovascular outcomes in patients with T2D treated with or without SGLT2 inhibitors.

METHODS:

Post hoc analysis of Harmony Outcomes (Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease) evaluating the effect of albiglutide in T2D with cardiovascular disease by background SGLT2 inhibitor use. Additionally, a trial-level meta-analysis of Harmony Outcomes and AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes), which evaluated T2D with cardiovascular or renal disease, was performed, combining the treatment effect estimates according to SGLT2 inhibitor use.

RESULTS:

Of the 9,462 participants in Harmony Outcomes, 575 (6.1%) were treated with SGLT2 inhibitors at baseline. The effect of albiglutide on reducing the composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular events) was consistent with or without SGLT2 inhibitors (P interaction = 0.70). The effect of albiglutide on secondary outcomes and adverse events was not modified by SGLT2 inhibitors. A meta-analysis of Harmony Outcomes and AMPLITUDE-O included 13,538 patients, of whom 1,193 (8.8%) used SGLT2 inhibitors. Compared to placebo, GLP1-RAs reduced major adverse cardiovascular events without effect modification by SGLT2 inhibitor use (HR: 0.77; 95% CI: 0.68-0.87 without SGLT2 inhibitors; and HR: 0.78; 95% CI: 0.49-1.24 with SGLT2 inhibitors) (P for interaction = 0.95) and reduced heart failure hospitalization (HR: 0.72; 95% CI: 0.55-0.92 vs HR: 0.34; 95% CI: 0.12-0.96) (P for interaction = 0.18).

CONCLUSIONS:

In patients with T2D and cardiovascular disease, GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use. These findings suggest that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk. Clinical trials with combination therapy are needed.

01 Aug 2023·International journal of cardiology. Heart & vasculature

Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes

Review

Author: Almasry, Ibrahim O ; Rashba, Eric J ; Aslam, Faisal M ; Tao, Michael ; Al-Sadawi, Mohammed A ; Alsaiqali, Mahmoud ; Singh, Abhijeet ; Fan, Roger

Background:

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) are frequently used for the management of diabetes. The impact of GLP-1 RA on cardiovascular outcomes is unclear. We aim to assess the effect of GLP-1 RA on mortality, atrial and ventricular arrhythmias, and sudden cardiac death in patients with type II diabetes.

Methods:

We searched databases including Ovid MEDLINE, EMBASE, Scopus, Web of Science, Google Scholar and CINAHL, from inception to May 2022, for randomized controlled trials reporting the relationship between GLP-1 RA (including albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide) and mortality, atrial arrhythmias, and the combined incidence of ventricular arrhythmias and sudden cardiac death. The search was not restricted to time or publication status.

Results:

A total of 464 studies resulted from literature search, of which 44 studies, including 78,702 patients (41,800 GLP-1 agonists vs 36,902 control), were included. Follow up ranged from 52 to 208 weeks. GLP-1 RA were associated with lower risk of all-cause mortality (odds ratio 0.891, 95% confidence interval 0.837-0.949; P < 0.01) and reduced cardiovascular mortality (odds ratio 0.88, 95% confidence interval 0.881-0.954; P < 0.01). GLP-1 RA were not associated with increased risk of atrial (odds ratio 0.963, 95% confidence interval 0.869-1.066; P 0.46) or ventricular arrhythmias and sudden cardiac death (odds ratio 0.895, 95% confidence interval 0.706-1.135; P 0.36).

Conclusion:

GLP-1 RA are associated with decreased all-cause and cardiovascular mortality, and no increased risk of atrial and ventricular arrhythmias and sudden cardiac death.

News (Medical) associated with Albiglutide

27 Jun 2024

·www.drugs.com

Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD

THURSDAY, June 27, 2024 -- For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide , is effective for weight loss, while preserving bone health, according to a study published online June 25 in JAMA Network Open . Simon Birk Kjær Jensen, Ph.D., from the University of Copenhagen in Denmark, and colleagues examined bone health at clinically relevant sites after diet-induced weight loss followed by a one-year intervention with exercise, liraglutide, or both in a secondary analysis of a randomized trial involving adults aged 18 to 65 years with obesity, without diabetes. After an eight-week low-calorie diet, participants were randomly allocated to exercise alone, the GLP-1 RA liraglutide alone, the combination, or placebo for 52 weeks (48, 49, 49 and 49 participants, respectively). The researchers found that the total estimated mean change in weight losses during the study was 7.03 kg in the placebo group and 11.19, 13.74, and 16.88 kg in the exercise, liraglutide, and combination groups, respectively. Bone mineral density (BMD) was unchanged in the combination group versus the placebo group at the hip and lumbar spine. BMD decreased for the liraglutide versus the exercise group at the hip and spine (mean changes, −0.013 and −0.016 g/cm 2 , respectively). "Our findings highlight the importance of combining exercise with GLP-1 RA treatment for bone health," the authors write. Novo Nordisk supplied the liraglutide and placebo pens; Cambridge Weight Plan supplied low-calorie meal replacement products. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

26 Jun 2024

·www.echemi.com

Novo Nordisk's Semaglutide - A Breakthrough in Obesity Management

Semaglutide, the active ingredient in Novo Nordisk's Wegovy®, is a GLP-1 receptor agonist that works by binding to and activating the GLP-1 receptor, thereby exerting its effects in the treatment of obesity. Given that the GLP-1 receptor is involved in the specific brain regions that regulate appetite, the application of Wegovy® in obese patients can significantly reduce hunger, enhance satiety, and decrease food cravings, thereby assisting patients in reducing caloric intake and achieving weight loss. Moreover, through genetic engineering, Wegovy® has been successful in extending its half-life to 7 days, allowing for a once-weekly dosing regimen, providing Chinese patients with a safe and convenient weight management solution. Zhangkezhou, the Corporate Vice President of Pharmaceutical Quality at Novo Nordisk Greater China, stated that Novo Nordisk's research in the field of obesity treatment has spanned over 25 years, and the company has established a solid scientific foundation based on GLP-1RA therapy. The company is committed to comprehensively addressing the overall health of obese patients and aims to provide them with an integrated treatment plan. Looking ahead, Novo Nordisk will continue to lead the innovative breakthroughs in the field of obesity treatment to meet the diverse medical needs of Chinese patients. Zhou Xiaping, the Global Senior Vice President and President of Novo Nordisk Greater China, emphasizes that as a global leader in the field of obesity treatment, Novo Nordisk is dedicated to changing the world's perception, prevention, and treatment of obesity. Coinciding with Novo Nordisk China's 30th anniversary, Wegovy® as the company's latest innovative drug introduced to China will effectively address the unmet medical needs in the field of obesity treatment in China. The company is grateful for the support and guidance from the National Medical Products Administration and relevant government departments in accelerating the introduction of innovative drugs to China, as well as the contributions of researchers and participants in the clinical trials. Novo Nordisk will uphold its mission of "driving change and working together to overcome serious chronic diseases" and focus on patient-centricity, accelerating innovation, and diversifying and comprehensively contributing to the prevention and treatment of chronic diseases in China, supporting the "Healthy China 2030" initiative. It is hereby declared that the approved Wegovy® (for long-term weight management in adults) and the already marketed Ozempic® (for the treatment of type 2 diabetes in adults) are both prescription drugs, targeting different diseases and cannot be substituted for each other. About Wegovy® (semaglutide injection for long-term weight management) Wegovy® is the world's first and currently the only once-weekly GLP-1RA for long-term weight management, providing not only significant weight loss but also multiple health benefits. Wegovy® has been launched in over 10 countries and regions globally. Wegovy® is indicated for long-term weight management in adults with an initial body mass index (BMI) of: - BMI ≥ 30 kg/m² (obesity) - BMI 27 kg/m² to < 30 kg/m² (overweight) with at least one weight-related comorbidity, such as prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Wegovy® can achieve an average weight loss of 17% (16.8 kg) and provide multiple health benefits, including reduced waist circumference, decreased visceral fat, improved lipid profile, and delayed progression to type 2 diabetes. In the global STEP clinical trial series covering over 25,000 overweight and obese participants, as well as real-world data studies, Wegovy® has demonstrated good safety and tolerability. Its active ingredient, semaglutide, has up to 94% structural homology with human GLP-1 and has been extensively validated for its safety, used by 5.4 million patients globally. The most common adverse reactions of Wegovy® are mild to moderate transient gastrointestinal events. About the STEP Clinical Trial Series The STEP clinical trial series for Wegovy® (semaglutide injection for long-term weight management) started in June 2018 and has completed 14 trials to date, including 12 global Phase 3 trials, 1 regional Phase 3 trial in East Asia, and 1 regional Phase 3 trial primarily in China. These trials have study durations of 11-24 months, with an average maximum treatment period of 34 months, aiming to evaluate the efficacy, safety, and other health benefits of Wegovy® in the long-term weight management of adults. Overall, the STEP clinical trial data have shown that Wegovy® can significantly reduce the weight of adult overweight and obese patients across different regions, ethnicities, ages, and genders, with or without type 2 diabetes, with an average weight loss of 17% (16.8 kg), and has demonstrated good safety and tolerability.

Phase 3Drug ApprovalClinical Result

25 Jun 2024

·www.biospace.com

Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes

Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it has closed an oversubscribed Series C financing totaling $88 million. The new capital will be used to complete the pivotal ReCET Clinical Study, which has been granted an Investigational Device Exemption (IDE) by the U.S. Food and Drug Administration (FDA). A group of new investors, including Hatteras Venture Partners, Lumira Ventures, and Orlando Health Ventures, joined an undisclosed strategic lead investor and existing investors Intuitive Ventures, Longitude Capital, Mayo Clinic, and Santé Ventures in the Series C funding. "We are excited to take this significant step forward in our mission to transform diabetes care," said Stacey Pugh, CEO of Endogenex. "This funding will enable us to complete our pivotal clinical study, bringing us closer to offering a groundbreaking solution for type 2 diabetes patients. The therapeutic landscape in diabetes continues to evolve, especially around the earlier use of SGLT2i and GLP-1RA. However, there remains a considerable unmet need to address the underlying pathophysiology and progression of the disease." "We are very proud of the company's progress, and this successful funding round is a testament to Endogenex's innovative technology," said Juliet Tammenoms Bakker, Endogenex Board Chair and Managing Director at Longitude Capital. "This milestone underscores our investors' confidence in the company's vision and the impact it can make in treating the epidemic of type 2 diabetes around the world." About the ReCET Clinical Study The ReCET Clinical Study is a multicenter, prospective, randomized, double-blinded, sham-controlled study assessing the safety and effectiveness of the ReCET System. The pivotal study received IDE approval in November 2023. The study will enroll up to 350 patients at clinical sites in the United States and Australia. About the ReCET™ Procedure ReCET is a novel, endoscopic outpatient procedure that targets the cellular pathology of the duodenum. This pathology may contribute to the development and progression of type 2 diabetes. The ReCET System aims to initiate the body's natural regenerative process by applying highly controlled, non-thermal pulsed electric fields to the mucosa and sub-mucosa duodenal tissue. This approach may help restore proper cellular signaling from the duodenum and improve metabolic function, including better control of blood glucose levels. The ReCET System has been evaluated in feasibility clinical studies, such as REGENT-1 US, REGENT-1 Australia, and EMINENT in the Netherlands. These studies assessed the safety and efficacy of the treatment in adults with type 2 diabetes whose blood glucose levels were inadequately controlled despite using insulin and non-insulin medications. Preliminary outcomes from these studies have been presented at medical conferences globally. The ReCET System has received an FDA Breakthrough Device Designation for treating type 2 diabetes in adults inadequately controlled by glucose-lowering medications. About Endogenex™ Endogenex, founded in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). The company's innovations focus on resetting the body's metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in T2D therapy, helping patients regain control of their blood glucose levels and slow disease progression. For more information, please visit . Media Inquiries: Brent Collins bcollins@endogenex.com +1(612) 227-6949

Clinical Study

100 Deals associated with Albiglutide

External Link

KEGG	Wiki	ATC	Drug Bank
D08843	Albiglutide	A10BJ04	DB09043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	EU	GlaxoSmithKline Trading Services Ltd.	20 Mar 2014
Diabetes Mellitus, Type 2	IS	GlaxoSmithKline Trading Services Ltd.	20 Mar 2014
Diabetes Mellitus, Type 2	LI	GlaxoSmithKline Trading Services Ltd.	20 Mar 2014
Diabetes Mellitus, Type 2	NO	GlaxoSmithKline Trading Services Ltd.	20 Mar 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Phase 2	FR	GSK Plc	10 Oct 2014
Diabetes Mellitus, Type 1	Phase 2	DE	GSK Plc	10 Oct 2014
Diabetes Mellitus, Type 1	Phase 2	IT	GSK Plc	10 Oct 2014
Diabetes Mellitus, Type 1	Phase 2	ES	GSK Plc	10 Oct 2014
Diabetes Mellitus, Type 1	Phase 2	GB	GSK Plc	10 Oct 2014
Hypoglycemia	Phase 2	US	GSK Plc	01 Dec 2011
Heart failure NYHA class III	Phase 2	US	GSK Plc	15 Sep 2010
Heart failure NYHA class III	Phase 2	GB	GSK Plc	15 Sep 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2022	Not Applicable	Fractures, Bone	-	GLP-1RA	uhfzkhwpoa(zapqnflyrr): HR = 0.89 (95% CI, 0.76 - 1.05)	Positive	22 Sep 2022
				DPP-4i
NCT02229227 (Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	814	optimized basal insulin glargine+ lispro+Albiglutide	lsssfizlvy(shipajnsro) = rucpusxixy glccegniur (pusxjpiunf, 0.8) View more	Positive	01 Oct 2020
				optimized basal insulin glargine+ lispro	lsssfizlvy(shipajnsro) = kkbsfgfwim glccegniur (pusxjpiunf, 0.8) View more
NCT02284009 (Pubmed \| J Clin Endocrinol Metab) Manual	Phase 2	Diabetes Mellitus, Type 1	67	insulin+Albiglutide	bbugomwxja(vaxcrktrqd) = uskegwgybw gqwqmtekkl (rlzjhdvaxa )	Negative	01 Jun 2020
				insulin+Placebo	bbugomwxja(vaxcrktrqd) = ebgdxmjfpd gqwqmtekkl (rlzjhdvaxa )
NCT02660736 (Pubmed)	Phase 1	-	59	Albiglutide liquid formulation	ekibiofmzm(hdlzrdrzeh) = ngglsrqtzr ufdfrgrqtq (gzraatjlxx ) View more	-	01 Apr 2019
				Lyophilized albiglutide	ekibiofmzm(hdlzrdrzeh) = dsfziyikhe ufdfrgrqtq (gzraatjlxx ) View more
NCT02284009 (110933, CTgov)	Phase 2	Diabetes Mellitus, Type 1	67	Insulin (Placebo)	kpvgjmfjea(rdxzaevfpv) = rptutbgpea rmtkfrqnmr (qyghiulaqz, fxjyipdufi - ksefptoups) View more	-	25 Mar 2019
				Insulin+Albiglutide weekly injection (Albiglutide)	kpvgjmfjea(rdxzaevfpv) = mbomosxmmx rmtkfrqnmr (qyghiulaqz, noqtqglmpq - zetdevxzad) View more
NCT02465515 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	9,463	Albiglutide matching placebo (Placebo)	aqilcxbtid(upfhiatjhy) = alnqpqsirs yhxnlcfcuv (gktkbcawks, plxwvctcyz - chjsrxatcd) View more	-	06 Mar 2019
				Albiglutide 30 mg (Albiglutide)	aqilcxbtid(upfhiatjhy) = ivwztcbucu yhxnlcfcuv (gktkbcawks, kkganydzui - pltrijkrfd) View more
NCT02465515 (Pubmed \| Lancet) Manual	Phase 4	Diabetes Mellitus, Type 2 \| Cardiovascular Diseases	9,463	standard therapy+albiglutide	iopqkfissu(xoikwqqjnn) = dtehtnolha wcfhqzrjxw (jtqxhggpch ) View more	Positive	27 Oct 2018
				standard therapy+Placebo	iopqkfissu(xoikwqqjnn) = zpekqqbfvx wcfhqzrjxw (jtqxhggpch ) View more
NCT02229227 (200977, CTgov)	Phase 3	Diabetes Mellitus, Type 2	814	Albiglutide+Insulin Glargine (Albiglutide + Insulin Glargine)	aenfcmwlgi(akmflnsouo) = xcjjjhceoo lzhueqwcic (kvzaywbwtb, cnmlpygsyg - lgarowbejc) View more	-	29 Jun 2018
				Insulin Lispro+Insulin Glargine (Insulin Lispro + Insulin Glargine)	aenfcmwlgi(akmflnsouo) = xxtlwmynch lzhueqwcic (kvzaywbwtb, xpilhwhlbz - goqplzslel) View more
NCT02683746 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	308	Lyophilized albiglutide DCC pen injector matching placebo+Albiglutide liquid auto-injector (Albiglutide Active LAI Plus Placebo Lyophilized DCC PI)	kyfiqdcyrk(kgaeqdlxyz) = wtlwpyuwzw gmoprkdsuu (akftrehmab, npbbbloldc - zdyfovtlxk) View more	-	30 May 2018
				Albiglutide liquid auto-injector matching placebo+Lyophilized albiglutide DCC pen injector (Albiglutide Lyophilized DCC PI Plus Placebo LAI)	kyfiqdcyrk(kgaeqdlxyz) = qzrpwnvwit gmoprkdsuu (akftrehmab, camskimgpi - brvuqvvfce) View more
NCT02793154 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	4	Exenatide (Part A: Exenatide SC Injection)	xkxiqkbyiz(ubzblefsjr) = pihatlxhzr xydfgqfdhu (algqfiadbf, oqebgjykhl - nlagmismij) View more	-	23 May 2018
				Exenatide (Part B: Exenatide SC Injection)	maqiqfqakn(dpxqpgjrgq) = nlgidsgxbx sgdoodbcdb (uoebkmhoqt, zqxekwvfej - vnsxpgcaub) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis